Executive Director, Business Development at Neurocrine Biosciences
Samir Siddhanti is the Executive Director of Business Development at Neurocrine Biosciences, a neuroscience-focused, biopharmaceutical company. Since 2017, he has helped Neurocrine expand its pipeline through collaborations with Idorsia Pharmaceuticals, Sosei Heptares, Takeda Pharmaceuticals, Voyager Therapeutics, and Xenon Pharmaceuticals. Additionally, Mr. Siddhanti is the Program Team Lead for Neurocrine’s Muscarinic Agonist Portfolio, including NBI-1117568, a selective M4 agonist in Phase 2 development for the treatment of schizophrenia.Prior to joining Neurocrine, Mr. Siddhanti worked at Goldman Sachs & Co. for five years in the Global Investment Research Division. He holds a B.S. and M.S. from Stanford University, where he graduated with university distinction.